Edition:
India

People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

3.68USD
6 Dec 2019
Change (% chg)

$-0.03 (-0.81%)
Prev Close
$3.71
Open
$3.79
Day's High
$3.85
Day's Low
$3.66
Volume
334,515
Avg. Vol
398,741
52-wk High
$17.79
52-wk Low
$2.27

Buchen, David 

Mr. David A. Buchen is a Senior Vice President, Chief Legal Officer and Corporate Secretary of the Company. David is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in the pharmaceutical industry, with notable expertise driving corporate value creation through world-class legal strategies supporting corporate securities, IP, anti-trust, employment, litigation and Mergers & Acquisitions (M&A). Most recently, David served as a consultant to the pharmaceutical industry, providing counsel to various global and U.S. manufacturing, marketing and distribution companies. Prior to establishing his consultancy, he held several executive leadership roles, including serving as EVP – Commercial, North American Generics and International as well as 12 years as Chief Legal Officer and Corporate Secretary supporting Watson Pharmaceuticals’ growth and transformation from a US-focused $500 million generic pharmaceutical company to a $16 billion global specialty leader rebranded as Actavis, plc. David holds a Bachelor of Arts degree from the University of California at Berkeley and a Juris Doctor degree from the George Washington University Law School. He has been recognized by the National Law Journal as one of the Top 50 General Counsels in the U.S.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --